FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours

Wiener Medizinische Wochenschrift

Volumn 162, Issue 19-20, 2012, Pages 423-429

  Malle, Philipp ^a   Sorschag, Manfred ^a   Gallowitsch, Hans Jürgen ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

FDG PET; FDG PET CT; Gastrointestinal stromal tumours (GISTs); Treatment response assessment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; SUNITINIB;

ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK POPULATION; HUMAN; LABELING INDEX; LUNG LESION; METABOLISM; METASTASIS; MITOSIS RATE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BLOOD GLUCOSE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PYRIMIDINES; PYRROLES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84871528258     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-012-0131-y     Document Type: Article

References (31)

1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-65.
2. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-69.
3. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-80.
4. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213-20.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors-de-fnition, clinical, histological, immunohistochemical, and molecular genetic features and diferential diagnosis. Vir-chows Arch. 2001;438:1-12.
6. Dematteo RP, Maki RG, Antonescu C, et al. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg. 2003;40:144-93.
7. Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol. 2000;1:267-73.
8. Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stro-mal tumors: diferences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000;18:3211-20.
9. Druker BJ, Tamura S, Buchdunger E, et al. Efects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-6.
10. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002; 33:484-95.
11. Demetri GD, von Mehren M, Blanke CD, et al. Efcacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
12. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stro-mal tumors are predicted by diferent prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23:5795-804.
13. Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol. 2007;18 Suppl 10:20-4.
14. Otomi Y, Otsuka H, Morita N, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270-4.
15. Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fuorodeo-xyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stro-mal tumors. World J Surg. 2005;29:1429-35.
16. Gayed I, Vu T, Iyer R, et al. Te role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
17. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of ima-tinib (STI571) therapy in patients with gastrointestinal stro-mal tumors. J Nucl Med. 2004;45:357-65.
18. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-8.
19. Ghanem N, Altehoefer C, Furtwängler A, et al. Computed tomography in gastrointestinal stromal tumors. Eur Radiol. 2003;13:1669-78.
20. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET fndings. Am J Roentgenol. 2004;183:1619-28.
21. Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003;226:527-32.
22. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-9.
23. Shinto A, Nair N, Dutt A, et al. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med. 2008;33:486-7.
24. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fuoro-deoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82.
25. Jager PL, Gietema JA, Van Der Graaf WT. Imatinib mesy-late for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004;25:433-8.
26. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesy-late in patients with gastrointestinal stromal tumor. Am J Roentgenol. 2007;189:324-30.
27. Goerres GW, Stupp R, Barghouth G, et al. Te value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-62.
28. Heinicke T, Wardelmann E, Sauerbruch T, et al. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fuoro-deoxyg-lucose-positron emission tomography. Anticancer Res. 2005;25:4591-4.
29. Hong X, Choi H, Loyer EM, et al. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiogra-phics. 2006;26:481-95.
30. Van Den Abbeele AD. Te lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13 Suppl 2:8-13.
31. Van Den Abbeele AD, Badawi RE, Manola J, et al. Efects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol 2004;22 Suppl 14:198.